WAVEMAN · COMPANY

LMAT · Lemaitre Vascular Inc

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

LMAT

Name: LEMAITRE VASCULAR INC (LMAT) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

LEMAITRE VASCULAR INC

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001158895

FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$7.0M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

171

13F, latest reported quarter

REVENUE GROWTH

+13.5%

XBRL, annual

NET MARGIN

23.1%

CONVERSIONS · 180D

codes C/M, not in net · $796.2K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$7.0M over 180 days

below 80% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

171 funds added or opened last quarter

more than 72% of Medical Devices

REVENUE

+13.5% year over year

more than 62% of Medical Devices

MARGIN

23.1% net margin

more than 95% of Medical Devices

BUYBACKS

$477.0K repurchased, FY to 2026-06-30

below 90% of Medical Devices

SHORT

6.3% of shares outstanding short · 5.6 days to cover · settled 2026-07-31

more than 73% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$7.0M across 5 people in 180 days.

171 funds added or opened positions in the latest 13F quarter, of 330 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -14.7%

-14.7%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $7.0M sold by insiders over 180 days, 171 funds added last quarter, $449.2K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, LEMAITRE VASCULAR INC insiders sold a net $7.0M of stock across 112 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

LeMaitre George W

Chairman and CEO

SELL

2026-05-08

27,881.0

$3.0M

Kamke Trent G

Senior V. P., Operations

SELL

2026-05-08

2,928.0

$313.3K

LeMaitre George W

Chairman and CEO

SELL

2026-05-07

18,600.0

$2.0M

Ross Bridget A

Director

SELL

2026-05-07

5,044.0

$560.4K

Jasinski Lawrence J

Director

SELL

2026-05-07

3,943.0

$433.7K

112 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 107 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

3,272,973.0 sh

$314.1M

Conestoga Capital Advisors, LLC

1,367,513.0 sh

$131.2M

FIRST TRUST ADVISORS LP

1,093,502.0 sh

$104.9M

CONGRESS ASSET MANAGEMENT CO

963,706.0 sh

$92.5M

VANGUARD CAPITAL MANAGEMENT LLC

953,437.0 sh

$91.5M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

BRIDGET A ROSS

FILED 2026-07-29

$449.2K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

CONESTOGA SMALL CAP FUND

$104.0M POSITION · AS OF 2026-03-31

4.6%

GRANDEUR PEAK US STALWARTS FUND

$631.2K POSITION · AS OF 2026-04-30

3.6%

Bahl & Gaynor Small Cap Dividend ETF

$4.1M POSITION · AS OF 2026-03-31

3.1%

Rockefeller US Small Cap Core Fund

$2.6M POSITION · AS OF 2026-02-28

2.7%

Ranger Micro Cap Fund

$294.7K POSITION · AS OF 2026-04-30

2.5%

Congress Small Cap Growth Fund

$48.8M POSITION · AS OF 2026-04-30

2.5%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 8 registered trials, 5 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

0 ACTIVE

Not applicable

5 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2024

$3.2M

$8.3M

$1.1M

+169%

+35%

2020

$1.4M

$3.1M

$598.0K

+14%

+24%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$249.6M	$219.9M	$193.5M	$161.7M
GROSS PROFIT	$178.5M	$150.9M	$127.0M	$104.9M
OPERATING INCOME	$67.9M	$52.3M	$36.7M	$26.8M
NET INCOME	$57.7M	$44.0M	$30.1M	$20.6M
EPS (DILUTED)	2.52	1.93	1.34	0.93
OPERATING CASH FLOW	$81.3M	$44.1M	$36.8M	$25.4M
CASH	$28.2M	$25.6M	$24.3M	$19.1M
BUYBACKS	$1.8M	$1.7M	$853.0K	$642.0K
DIVIDENDS PAID	$18.1M	$14.4M	$12.4M	$11.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE